Damien McDevitt, President and Chief Executive Officer and Director of Aspen Neuroscience, Inc., filed a Form 3 initial statement of beneficial ownership with the SEC on October 29, 2026, reporting his securities holdings as of that date.

Key Highlights

  • Reporting person: Damien McDevitt, serving as both Director and President and Chief Executive Officer of Aspen Neuroscience, Inc. (NASDAQ:ASPE).
  • Family trust holdings: 485,751 shares of Common Stock held indirectly through the Marnell-McDevitt Family Trust dated May 2, 2019, of which 93,607 shares remain subject to performance-based vesting conditions and potential repurchase by the issuer.
  • Children's irrevocable trusts: 25,299 shares each held indirectly through three separate 2025 irrevocable trusts for Finn McDevitt, Aran McDevitt, and Conor McDevitt, totaling 75,897 shares.
  • Stock option 1: Option to purchase 196,820 shares of Common Stock at $8.70 per share, granted December 16, 2024, expiring December 15, 2034, reported as fully vested and exercisable.
  • Stock option 2: Option to purchase 387,063 shares of Common Stock at $5.74 per share, granted November 26, 2025, expiring November 25, 2035, with vesting schedule amended in August 2026.
  • Filing date: October 29, 2026, the same date listed as the event requiring the statement.

McDevitt's Beneficial Ownership Structure at Aspen Neuroscience

According to the filing, Damien McDevitt holds no shares of Common Stock directly in Table I. His indirect non-derivative holdings consist of four separate line items. The largest is 485,751 shares held through the Marnell-McDevitt Family Trust dated May 2, 2019, co-trusteed by McDevitt and Pamela Marnell-McDevitt. The filing notes that 93,607 of those shares "remain subject to performance-based vesting conditions and to repurchase by the Issuer if such conditions are not met or upon termination of the Reporting Person's service."

The remaining indirect holdings consist of 25,299 shares each in three irrevocable trusts established in 2025 for Finn McDevitt, Aran McDevitt, and Conor McDevitt, each acting as their own trustee, according to the filing's footnotes. On the derivative side, McDevitt holds two stock options directly. The first, granted December 16, 2024, covers 196,820 shares at an exercise price of $8.70 and is reported as fully vested and exercisable, with an expiration date of December 15, 2034.

The second option, granted November 26, 2025, covers 387,063 shares at $5.74 per share and expires November 25, 2035. The filing discloses that the vesting schedule for this option was amended in August 2026, such that unvested shares as of July 20, 2026, "shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date." The form was signed by Jeffrey L. Boerneke as Attorney-in-Fact under an attached power of attorney.

What Was Disclosed

Damien McDevitt filed a Form 3 initial beneficial ownership statement for Aspen Neuroscience, Inc. (NASDAQ:ASPE) on October 29, 2026, disclosing indirect Common Stock holdings across four trusts and two directly held stock options covering a combined 583,883 shares.